QR kód

Bevacizumab increases the sensitivity of olaparib to homologous recombination-proficient ovarian cancer by suppressing CRY1 via PI3K/AKT pathway

PARP inhibitors have changed the management of advanced high-grade epithelial ovarian cancer (EOC), especially homologous recombinant (HR)-deficient advanced high-grade EOC. However, the effect of PARP inhibitors on HR-proficient (HRP) EOC is limited. Thus, new therapeutic strategy for HRP EOC is de...

Celý popis

Uloženo v:
Hlavní autoři: Yasushi Iida, Nozomu Yanaihara, Yuki Yoshino, Misato Saito, Ryosuke Saito, Junya Tabata, Ayako Kawabata, Masataka Takenaka, Natsuko Chiba, Aikou Okamoto
Médium: Artigo
Jazyk:Inglês
Vydáno: Frontiers Media S.A. 2024-02-01
Edice:Frontiers in Oncology
Témata:
ovarian cancer
olaparib
bevacizumab
homologous recombinant proficient
CRY1
On-line přístup:https://www.frontiersin.org/articles/10.3389/fonc.2024.1302850/full
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Podobné jednotky